http://orcid.org/0000-0002-4760-3269
References
- Chande, N.; Patton, P. H.; Tsoulis, D. J.; et al. Azathioprine or 6-Mercaptopurine for Maintenance of Remission in Crohn's Disease. Cochrane Database Syst. Rev. 2015, 10, CD000067.
- Van Asseldonk, D. P.; de Boer, N. K.; Peters, G. J.; et al. On therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance. Curr. Drug. Metab. 2009, 10, 981–997.
- Ansari, A.; Aslam, Z.; De Sica, A.; et al. Influence of Xanthine Oxidase on Thiopurine Metabolism in Crohn's Disease. Aliment Pharmacol. Ther. 2008, 28, 749–757.
- Kiszka-Kanowitz, M.; Theede, K.; Mertz-Nielsen, A. Randomized Clinical Trial: A Pilot Study Comparing Efficacy of Low-Dose Azathioprine and Allopurinol to Azathioprine on Clinical Outcomes in Inflammatory Bowel Disease. Scand. J. Gastroenterol. 2016, 51, 1470–1475.
- Seinen, M. L.; van Asseldonk, D. P.; de Boer, N. K.; et al. The Effect of Allopurinol and Low-Dose Thiopurine Combination Therapy on the Activity of Three Pivotal Thiopurine Metabolizing Enzymes: Results from a Prospective Pharmacological Study. J. Crohns. Colitis. 2013, 7, 812–819.
- Satsangi, J.; Silverberg, M. S.; Vermeire, S.; et al. The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut. 2006, 55, 749–753.
- van Asseldonk, D. P.; de Boer, N. K.; Smid, K.; et al. Limited Intra-Individual Variability in Hypoxanthine-Guanine Phosphoribosyl Transferase, Thiopurine S-methyl Transferase, and Xanthine Oxidase Activity in Inflammatory Bowel Disease Patients during 6-Thioguanine Therapy. Nucleosides Nucleotides Nucleic Acids. 2010, 29, 284–290.
- Guerciolini, R.; Szumlanski, C.; Weinshilboum, R. M. Human Liver Xanthine Oxidase: Nature and Extent of Individual Variation. Clin. Pharmacol. Ther. 1991, 50, 663–672.
- Kudo, M.; Moteki, T.; Sasaki, T.; et al. Functional Characterization of Human Xanthine Oxidase Allelic Variants. Pharmacogenet Genomics. 2008, 18, 243–251.
- Hawwa, A. F.; Millership, J. S.; Collier, P. S.; et al. Pharmacogenomic Studies of the Anticancer and Immunosuppressive Thiopurines Mercaptopurine and Azathioprine. Br. J. Clin. Pharmacol. 2008, 66, 517–528.
- Madyastha, K. M.; Sridhar, G. R. A Novel Pathway for the Metabolism of Caffeine by a Mixed Culture Consortium. Biochem. Biophys. Res. Commun. 1998, 249, 178–181.
- Aranda, R.; Domenech, E.; Rus, A. D.; et al. Age-Related Increase in Xanthine Oxidase Activity in Human Plasma and Rat Tissues. Free. Radic. Res. 2007, 41, 1195–1200.
- Johnson, R. J.; Kang, D. H.; Feig, D.; et al. Is there a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension. 2003, 41, 1183–1190.
- Stiburkova, B.; Bleyer, A. J. Changes in Serum Urate and Urate Excretion with Age. Adv. Chronic. Kidney. Dis. 2012, 19, 372–376.
- Gisbert, J. P.; Chaparro, M. Systematic Review with Meta-Analysis: Inflammatory Bowel Disease in the Elderly. Aliment. Pharmacol. Ther. 2014, 39, 459–477.
- Boda, M.; Nemeth, I.; Boda, D. The Caffeine Metabolic Ratio as an Index of Xanthine Oxidase Activity in Clinically Active and Silent Celiac Patients. J. Pediatr. Gastroenterol. Nutr. 1999, 29, 546–550.
- Ishikita, H.; Eger, B. T.; Okamoto, K.; et al. Protein Conformational Gating of Enzymatic Activity in Xanthine Oxidoreductase. J. Am. Chem. Soc. 2012, 134, 999–1009.